To learn more about Life Chemicals and the services it provides, Technology Networks spoke with Olga Balabon. In this interview, Olga also highlights how the company supports researchers when searching for appropriate product candidates.

While many of us are still attending events remotely, ASMS 2021 has been in full swing this year with in-person talks and events. To give you a taste of the topics proving popular this year, Technology Networks has produced a round up to highlight a selection of key themes and innovations.

The focus on COVID-19 has caused many trials to be delayed, canceled or scaled back – meaning that the development of new medicines for patients in other areas has been slowed. At the same time, it has exposed pre-existing flaws in the industry. To recover from the pandemic, the industry must now address these underlying issues.

In this interview, Alexandra Richardson tells us more about her research, the role that technology is playing in it and how important industry partnerships have been.

To learn more about the Biophase 8800 system and how it can help to overcome current bioanalytical challenges, Technology Networks spoke to Mani Krishnan, vice president and general manager, SCIEX CE and Biopharma.

Poor mental health is a growing burden on global healthcare systems. In this opinion piece, Compass Pathways chief medical officer Professor Guy Goodwin reviews currently available treatments options and the results from his company's new clinical trial into the efficacy of the psychedelic psilocybin in treating mental health conditions.

To find out more about how AI can improve melanoma diagnosis, Technology Networks spoke to Dr. Kiran Motaparthi, director of dermatopathology and clinical associate professor of dermatology at the University of Florida and Julianna Ianni, PhD, vice president of AI R&D, Proscia.

What benefits can insect protein offer? How are regulatory frameworks impacting innovation in this field? And what can be done to drive further advances? Technology Networks had the pleasure of speaking with Thomas Farrugia, chief executive officer of Beta Bugs Limited, to answer these questions and more.

To learn more about a universal vaccine technology and how the platform could be applied to Alzheimer's disease and other neurological indications, Technology Networks spoke with Roman Kniazev, chief executive officer at Nuravax.

There is an inherent link between academia and industry that rarely gets the acknowledgement it deserves. Hear from a roundtable of PhD students on the impact that the collaborative relationship between academia and industry has on their work and the role that technology plays in the “Science Futures” initiative.